Frontier Space Technologies
Develops autonomous miniaturized laboratories and bioreactor platforms for pharmaceutical research and biomanufacturing in microgravity
Frontier Space Technologies develops autonomous laboratory systems for conducting pharmaceutical research and biomanufacturing in microgravity. Founded in 2021 as a spinout from Cranfield University, the company builds SpaceLab, a modular, autonomous lab-in-a-box designed to support in-orbit experiments including protein crystallography, cell culture, and precision fermentation. The company also develops a larger bioreactor platform for on-orbit manufacturing of high-value bioproducts. Frontier Space offers end-to-end microgravity research services with custom sample containers, microfluidics chips, onboard imaging, environmental monitoring, and active thermal management. The company has flown two EGGS (Early Gen micro-Gravity Service) missions: EGGS-1 aboard a SpaceX Falcon 9 in April 2025 as part of an ESA-funded project, and EGGS-2 on PSLV-C62 in January 2026 in partnership with Azenta Life Sciences and Orbital Paradigm. Headquartered at the Medical Technologies Innovation Facility at Nottingham Trent University, with a second facility at Space Park Leicester, the company serves pharmaceutical and life sciences customers seeking to leverage microgravity for drug discovery and bioprocessing.
Provides a cloud-based software platform for satellite mission design, digital twin simulation, flight software, and constellation operations
Operates orbital transfer vehicles for last-mile satellite delivery, hosted payload services, space cloud computing, and in-orbit servicing
Designs and operates automated microgravity research and manufacturing facilities aboard the ISS and develops free-flying orbital platforms